Modern Health vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 41)
Modern Health logo

Modern Health

EmergingHealthcare

Mental Health Benefits

Modern Health is an enterprise mental health platform providing personalized therapy, coaching, and wellbeing resources to employees through employer-sponsored benefits programs. HQ: San Francisco.

AI VisibilityBeta
Overall Score
C41
Category Rank
#348 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
46
Perplexity
41
Gemini
37

About

Modern Health is an enterprise mental health platform that provides employees access to licensed therapists, mental health coaches, and digital wellness resources through their employer-sponsored benefits. Founded in 2017 by Alyssa Jaffee and Erica Johnson, Modern Health delivers a clinically validated mental health benefit that employers offer to their workforce as part of comprehensive health benefits packages — giving employees same-week access to therapy and coaching rather than waiting months for a mental health appointment through traditional insurance.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

41
Overall Score
81
#348
Category Rank
#17
75
AI Consensus
71
stable
Trend
stable
46
ChatGPT
80
41
Perplexity
75
37
Gemini
77
46
Claude
86
39
Grok
85

Key Details

Category
Mental Health Benefits
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Modern Health
Mental Health Benefits

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.